晚期喉癌患者血管内皮生长因子及其受体-2与诱导化疗预后的关系

Expression of VEGF and VEGFR-2 in patients with operable advanced laryngeal cancer treated with induction chemotherapy

目的分析血管内皮生长因子（VEGF）及其受体-2（VEGFR-2）在可手术切除的晚期喉癌诱导化疗患者中的表达及与预后的关系。方法回顾性分析49例晚期可手术喉癌患者，VEGF和VEGFR-2酶联免疫的量化分析。结果VEGF中、高表达34例，未表达或低表达15例。VEGFR-2中、高表达31例，未表达或低表达18例。VEGF、VEGFR-2同时中、高表达23例。VEGF、VEGFR。2同时未表达或低表达11例。VEGF的表达与诱导化疗明显相关。VEGF未表达或低表达的15例中，11例（73％）对诱导化疗完全反应。然而，VEGF中、高表达的34例中，仅12例（35％）完全反应（X^2=6．047，P〈0．05）。结论VEGF的表达可以预测喉癌患者对诱导化疗的有效性。

Objective To assess the prognostic values of the immunohistochemical expression of vascular endothelial growth factor （VEGF） and vascular endothelial growth factor receptor-2 （VEGFR-2） in a cohort of patients with operable advanced laryngeal cancer who have been treated with induction chemotherapy. Methods VEGF and VEGFR-2 expression in the Forty-nine patients was quantified by an enzyme immunosorbent assay in a retrospective series. Results The moderate to high VEGF expression in 34 patients were found and low expression in 15 patients. VEGFR-2 expression was moderate to high in 31 patients and was low expression in 18. The probability of a complete response to induction chemotherapy was significantly higher in patients with none to low VEGF expression. Conclusion VEGF expression seems to be a significant predictor of complete response to induction chemotherapy.